Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT04166487	Phase II	Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium	Plasma-Adapted First-Line Pembro in NSCLC	Active, not recruiting	USA	0
NCT03953235	Phase Ib/II	GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab	A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens	Completed	USA	0
NCT04222972	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)	Terminated	TUR \| SWE \| POL \| NOR \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUS \| ARG	6
NCT05435846	Phase I	Capmatinib + Trametinib	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	Terminated	USA	0
NCT05513703	Phase II	Telisotuzumab vedotin	A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA \| ITA \| ISR \| FRA \| DEU \| AUS	3
NCT05082610	Phase I	HMBD-002 HMBD-002 + Pembrolizumab	A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors	Completed	USA	0
NCT04925609	Phase Ib/II	Brigatinib	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED)	Recruiting	NLD \| FRA	0
NCT06834074	Expanded access	NVL-655	Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors (NVL-655-EAP)	Available	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| CHE \| CAN \| AUS	3
NCT02473497	Expanded access	Crizotinib	Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients	No longer available	USA	0
NCT05176665	Phase Ib/II	EMB-01	EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers	Recruiting	USA	1
NCT03679767	Phase II	Retifanlimab	A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)	Completed	USA \| ROU \| POL \| ITA \| HUN \| FRA \| ESP \| AUT	0
NCT03868423	Phase II	Brigatinib	Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers	Withdrawn	USA	0
NCT03166631	Phase I	BI 891065 + Ezabenlimab BI 891065	A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Terminated	USA	0
NCT05467748	Phase Ib/II	Pembrolizumab + Tulmimetostat	EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT03181308	Phase I	Carotuximab + Nivolumab	Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC	Completed	USA	0
NCT01121588	Phase I	Crizotinib	An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)	Terminated	USA \| ITA	5
NCT05384626	Phase Ib/II	Itraconazole + NVL-655 Midazolam + NVL-655 + Repaglinide NVL-655	A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	4
NCT03366766	Phase II	Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium	Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery	Terminated	USA	0
NCT03107988	Phase I	Cyclophosphamide + Lorlatinib + Topotecan Lorlatinib	NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)	Completed	USA \| GBR \| FRA \| CAN	0
NCT02823990	Phase II	MVA-MUC1-IL2 vaccine + Nivolumab	TG4010 and Nivolumab in Patients With Lung Cancer	Completed	USA	0
NCT03456063	Phase III	Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium	A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)	Completed	USA \| SWE \| SVN \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| AUT \| AUS	9
NCT07158489	Phase II	Gemcitabine + Ivonescimab	Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC (ORIGIN2)	Not yet recruiting	CHE	0
NCT03993873	Phase Ib/II	Elzovantinib	Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)	Active, not recruiting	USA \| FRA \| ESP	2
NCT04683250	Phase Ib/II	Vepafestinib	Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities (MARGARET)	Recruiting	USA	2
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Completed	DEU	0
NCT05083481	Phase Ib/II	ASP1570 + Pembrolizumab ASP1570 ASP1570 + Trifluridine-tipiracil hydrochloride ASP1570 + Docetaxel ASP1570 + Fluorouracil + Leucovorin + Oxaliplatin ASP1570 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ASP1570 + Fluorouracil + Irinotecan + Leucovorin	A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors	Terminated	USA \| FRA \| ESP	3
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| HUN \| GBR \| FRA \| ESP \| CAN \| AUS	3
NCT02638909	Phase II	Ceritinib	Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies	Terminated	USA	0

Profile Name	ALK act mut
Gene Variant Detail	ALK act mut (gain of function)
Relevant Treatment Approaches	ALK Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting